Journal of Pain & Palliative Care Pharmacotherapy最新文献_第4页

Improving Postoperative Acute Pain Management and Accelerating Discharge: The Role of the ERAS Pathway in Overweight Patients Undergoing Endometrial Cancer Surgery. 改善术后急性疼痛管理和加速出院：ERAS通路在超重子宫内膜癌手术患者中的作用。

IF 1.3

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2026-09-01 Epub Date: 2026-05-13 DOI: 10.1080/15360288.2026.2666277

Virginia Manetti, Federica Perelli, Emanuele A Fera, Stefano Secchi, Laura Salucci, Eleonora Gemmi, Caterina Stera, Cecilia Pantanelli, Silvio Cantini, Alberto Mattei, Marco Giusti, Giuseppe Vizzielli, Stefano Restaino, Piercarlo Ballo, Duccio Conti

{"title":"Improving Postoperative Acute Pain Management and Accelerating Discharge: The Role of the ERAS Pathway in Overweight Patients Undergoing Endometrial Cancer Surgery.","authors":"Virginia Manetti, Federica Perelli, Emanuele A Fera, Stefano Secchi, Laura Salucci, Eleonora Gemmi, Caterina Stera, Cecilia Pantanelli, Silvio Cantini, Alberto Mattei, Marco Giusti, Giuseppe Vizzielli, Stefano Restaino, Piercarlo Ballo, Duccio Conti","doi":"10.1080/15360288.2026.2666277","DOIUrl":"10.1080/15360288.2026.2666277","url":null,"abstract":"Enhanced Recovery After Surgery (ERAS) protocols have increasingly been adopted in gynecologic oncology. This study evaluates their effectiveness in patients undergoing endometrial cancer surgery, focusing on length of hospital stay (LOS), postoperative pain, and complications. A retrospective case-control study was conducted on patients treated between January 2019 and December 2024. Fifty patients managed with ERAS (Group 1) were compared with fifty patients treated with traditional care (Group 2). Groups were matched considering the American Society of Anesthesiologists physical status (ASA-PS) score, International Federation of Gynecology and Obstetrics (FIGO) stage, surgical approach, and age. Key outcomes analyzed were LOS, postoperative pain, analgesic use, and complications. Patients in the ERAS group had a significantly shorter length of stay (LOS) (p < .001), lower pain scores on the numeric rating scale (NRS) at 8, 16, 32, and 48 hours (p < .01-.001), but not at 40 hours (p = .13) at rest, and required fewer opioids (p < 0.001). Additionally, they experienced fewer nausea/vomiting episodes (p = .05). ERAS implementation in endometrial cancer surgery appears to improve recovery, reduce opioid use, and shorten hospitalization without compromising safety. These findings may support ERAS for optimizing perioperative outcomes, especially in overweight patients undergoing endometrial cancer surgery.","PeriodicalId":16645,"journal":{"name":"Journal of Pain & Palliative Care Pharmacotherapy","volume":" ","pages":"416-424"},"PeriodicalIF":1.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147930647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rethinking Pediatric Pain Management: A Call for a Socio-Clinical Approach. 重新思考儿科疼痛管理：呼吁社会临床方法。

IF 1.3

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2026-09-01 Epub Date: 2026-05-25 DOI: 10.1080/15360288.2026.2673919

Dhian Gowinda Luh Safitri, Kartika Rinakit Adhe

引用次数: 0

Administering Esomeprazole as a Continuous Subcutaneous Infusion in the Palliative Demographic: A Retrospective Review. 给予埃索美拉唑作为持续皮下输注在姑息人口统计学：回顾性回顾。

IF 1.3

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2026-09-01 Epub Date: 2026-07-13 DOI: 10.1080/15360288.2026.2700281

Jonathan Hindmarsh, Emma McDonald, Jonathan Pickard

引用次数: 0

Survey of Healthcare Professionals' Satisfaction and Perceived Impact on Quality of Care with Pharmacist-Led Pain Management Services. 药师主导的疼痛管理服务对医疗保健专业人员满意度和感知影响的调查。

IF 1.3

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2026-09-01 Epub Date: 2026-07-10 DOI: 10.1080/15360288.2026.2696983

Alice Chang, Danny Basri, Jasmine Jones, Arielle Spurley

引用次数: 0

Cannabinoids in the Treatment of Chemotherapy-Induced Peripheral Neuropathy: A Systematic Review of Randomized Controlled Trials. 大麻素治疗化疗诱导的周围神经病变：随机对照试验的系统评价。

IF 1.3

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2026-09-01 Epub Date: 2026-05-05 DOI: 10.1080/15360288.2026.2664668

Aritra Datta, Simon Erridge, Aditya Mukherjee, Ishita Acharya, Dhruv Vasooja, Uma Anand, Praveen Anand, Mikael H Sodergren

{"title":"Cannabinoids in the Treatment of Chemotherapy-Induced Peripheral Neuropathy: A Systematic Review of Randomized Controlled Trials.","authors":"Aritra Datta, Simon Erridge, Aditya Mukherjee, Ishita Acharya, Dhruv Vasooja, Uma Anand, Praveen Anand, Mikael H Sodergren","doi":"10.1080/15360288.2026.2664668","DOIUrl":"10.1080/15360288.2026.2664668","url":null,"abstract":"Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating toxicity of cancer treatment. Effective pharmacological treatments remain limited. Preclinical studies suggest cannabinoids reduce neuropathic pain through modulation of neurotransmission, neuroinflammation, and oxidative stress. However, clinical evidence in CIPN remains inconclusive. This systematic review evaluated the efficacy and safety of cannabis-based medicinal products (CBMPs) for the treatment or prevention of CIPN. A systematic search of PubMed MEDLINE, OVID EMBASE, and OVID MEDLINE was conducted to identify randomized controlled trials assessing CBMPs in adults with CIPN. Study selection, data extraction, and risk of bias assessment were performed independently by two reviewers using Cochrane Risk of Bias 2. Of 1,115 records identified, three double-blind randomized controlled trials with 68 participants and three ongoing trials met inclusion criteria. Interventions included nabiximols, oral cannabidiol, and topical cannabidiol. No study demonstrated improvement in pain or health-related quality of life compared with placebo (p > 0.050). Adverse events were mild to moderate, most commonly fatigue, dizziness, and dry mouth. Heterogeneity in study design, outcome measures, and follow-up prevented meta-analysis. Current evidence is insufficient to support the routine use of CBMPs for CIPN. Larger, methodologically rigorous trials with standardized outcomes and longer follow-up are required.","PeriodicalId":16645,"journal":{"name":"Journal of Pain & Palliative Care Pharmacotherapy","volume":" ","pages":"458-473"},"PeriodicalIF":1.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147839356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An Unrecognized Cause of Chronic Diarrhea: Opioid-Induced Adrenal Insufficiency - A Case Report. 慢性腹泻的一个未被认识的原因：阿片类药物引起的肾上腺功能不全- 1例报告。

IF 1.3

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2026-08-31 DOI: 10.1080/15360288.2026.2725827

David Kweku Aseda Donkor, Rejoice Abiodun, Parth Adrejiya, Winston Ugbajah, Cyril Anara

引用次数: 0

Acid-Suppressive Therapy in Inoperable Malignant Bowel Obstruction: A Systematic Review of the Available Evidence. 抑酸治疗不可手术恶性肠梗阻：现有证据的系统回顾。

IF 1.3

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2026-08-25 DOI: 10.1080/15360288.2026.2721404

Eva Gravdahl, Solveig Torvund, Olav Magnus Fredheim

{"title":"Acid-Suppressive Therapy in Inoperable Malignant Bowel Obstruction: A Systematic Review of the Available Evidence.","authors":"Eva Gravdahl, Solveig Torvund, Olav Magnus Fredheim","doi":"10.1080/15360288.2026.2721404","DOIUrl":"https://doi.org/10.1080/15360288.2026.2721404","url":null,"abstract":"Malignant bowel obstruction (MBO) is a common and distressing complication in advanced cancer. Histamine-2 receptor antagonists (H2RAs) and proton pump inhibitors (PPIs) are frequently used as part of multimodal medical management to reduce gastric secretions in MBO. This review aimed to assess whether clinical evidence supports acid‑suppressive therapy for symptom control in inoperable MBO. A systematic review was conducted in accordance with PRISMA 2020 guidelines. MEDLINE, Embase, CINAHL, CENTRAL, and Web of Science were searched to May 2024 and updated in February 2026. Studies reporting H2RA or PPI use for symptom management in MBO were eligible. Of 4,610 records identified, 20 studies met inclusion criteria. Included studies comprised randomized controlled trials, observational studies, case series, guidelines, and narrative reviews. No trial specifically evaluated the contribution of acid-suppressive therapy to symptom control in MBO. In available trials, H2RAs or PPIs were administered as background therapy in both arms, precluding assessment of their contribution to outcome. Observational data did not demonstrate consistent associations with improved clinical outcomes. Indirect evidence suggests modest reductions in gastric secretions. Despite widespread use and physiological plausibility, benefit has not been established in studies designed to evaluate effectiveness in MBO.","PeriodicalId":16645,"journal":{"name":"Journal of Pain & Palliative Care Pharmacotherapy","volume":" ","pages":"1-12"},"PeriodicalIF":1.3,"publicationDate":"2026-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148813218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Topical Menthol Cream for Refractory Localized Neuropathic Pain: A Multicenter Retrospective Study. 局部薄荷醇乳膏治疗难治性局部神经性疼痛：一项多中心回顾性研究。

IF 1.3

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2026-08-21 DOI: 10.1080/15360288.2026.2709501

Erwan Treillet, Marie Hélène Delmotte, Yacine Hadjiat, Nathan Moreau, Dubois Jacqueline, Massimo Lodi, Laure Serresse, Grégoire Oudot

{"title":"Topical Menthol Cream for Refractory Localized Neuropathic Pain: A Multicenter Retrospective Study.","authors":"Erwan Treillet, Marie Hélène Delmotte, Yacine Hadjiat, Nathan Moreau, Dubois Jacqueline, Massimo Lodi, Laure Serresse, Grégoire Oudot","doi":"10.1080/15360288.2026.2709501","DOIUrl":"https://doi.org/10.1080/15360288.2026.2709501","url":null,"abstract":"To assess the real-world effectiveness and tolerability of stepwise titration with compounded topical menthol in refractory localized neuropathic pain. We conducted a multicenter retrospective chart review in two French pain centers between March 2022 and September 2023. Adults with localized neuropathic pain, baseline pain intensity >4/10, DN4 ≥ 4, and previous treatment failure or intolerance received pharmacy-compounded menthol cream titrated from 1% to 10% over approximately 60 days. The primary endpoint was responder rate at the final concentration used, defined as ≥30% reduction in numerical rating scale pain intensity and/or ≥30% self-reported pain relief. Twenty-one patients were analyzed; 76% were women and 71% had chemotherapy-induced peripheral neuropathy. Mean pain intensity decreased from 6.83 at baseline to 4.82 at 10%, with significant improvement from 3% onward. At 10%, 12/21 patients met the response criterion. Treatment was generally well tolerated, with mostly mild transient local adverse effects. Progressively titrated topical menthol up to 10% may be a practical, accessible, and well-tolerated option for refractory localized neuropathic pain when systemic therapies are ineffective or poorly tolerated. These exploratory findings support titration-based use and warrant randomized placebo-controlled studies to confirm efficacy, refine dosing, and identify responder phenotypes.","PeriodicalId":16645,"journal":{"name":"Journal of Pain & Palliative Care Pharmacotherapy","volume":" ","pages":"1-9"},"PeriodicalIF":1.3,"publicationDate":"2026-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148794512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reduced Codeine Analgesic Efficacy Associated with Nicardipine in a Patient with Medication-Overuse Headache: A Case Report. 药物过度使用头痛患者与尼卡地平相关的可待因镇痛效果降低：一例报告。

IF 1.3

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2026-08-21 DOI: 10.1080/15360288.2026.2719868

Vincent Arcani, Nicolas Fabresse, Guillaume Hache, Anne Donnet

{"title":"Reduced Codeine Analgesic Efficacy Associated with Nicardipine in a Patient with Medication-Overuse Headache: A Case Report.","authors":"Vincent Arcani, Nicolas Fabresse, Guillaume Hache, Anne Donnet","doi":"10.1080/15360288.2026.2719868","DOIUrl":"https://doi.org/10.1080/15360288.2026.2719868","url":null,"abstract":"Codeine is a prodrug opioid whose analgesic efficacy depends on its bioactivation into morphine via cytochrome P450 2D6. Its use in migraine is discouraged because of limited efficacy, tolerance, and the risk of medication-overuse headache. Drug-drug interactions affecting its metabolism may further compromise pain control. We report the case of a 72-year-old man with chronic migraine and daily codeine use. A pharmacist-led medication review identified a potential pharmacokinetic interaction between codeine and extended-release nicardipine. Plasma concentrations of codeine and its metabolites were measured before and after codeine intake under nicardipine treatment and three months after substitution with candesartan. The fold increase in morphine-glucuronide concentration between baseline and peak rose from 1.6 with nicardipine to 3.5 after discontinuation, consistent with restored codeine bioactivation. This case highlights a clinically relevant interaction between nicardipine and codeine leading to reduced opioid efficacy. Beyond tolerance and medication-overuse headache, pharmacokinetic interactions should be systematically considered in patients with refractory pain.","PeriodicalId":16645,"journal":{"name":"Journal of Pain & Palliative Care Pharmacotherapy","volume":" ","pages":"1-6"},"PeriodicalIF":1.3,"publicationDate":"2026-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148794509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Suvorexant Prescription-Record Rates After a Palliative Care Pocket Manual Revision: A Single-Centre Interrupted Time Series Study. 姑息治疗袖套手册修订后的持续处方记录率：单中心中断时间序列研究。

IF 1.3

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2026-08-19 DOI: 10.1080/15360288.2026.2718165

Shinya Kajiura, Nobukazu Ryu, Shingo Chikaoka, Yuta Yagi, Naohiko Nakamura, Atsushi Kato, Ryuji Hayashi

{"title":"Suvorexant Prescription-Record Rates After a Palliative Care Pocket Manual Revision: A Single-Centre Interrupted Time Series Study.","authors":"Shinya Kajiura, Nobukazu Ryu, Shingo Chikaoka, Yuta Yagi, Naohiko Nakamura, Atsushi Kato, Ryuji Hayashi","doi":"10.1080/15360288.2026.2718165","DOIUrl":"https://doi.org/10.1080/15360288.2026.2718165","url":null,"abstract":"To examine whether a palliative care pocket manual revision suggesting suvorexant for nocturnal awakening was associated with changes in suvorexant prescription-record rates. We conducted a single-center retrospective interrupted time series study at a Toyama University Hospital using weekly prescription records for suvorexant (15 mg and 20 mg tablets combined). Prescription records, not unique patients, were analyzed with segmented negative binomial regression using an offset for days per week. The manual was updated on 16 May 2025; the first post-implementation week was 19 May 2025. The primary all-hospital series included 105 wk and 3,927 records. The immediate level change was in the direction of increase but statistically uncertain (IRR 1.34, 95% CI 0.88 to 2.05; p = 0.177), with no slope change (IRR per week 1.00, 95% CI 0.98 to 1.02; p = 0.888). Outpatient prescription-record rates showed a modest immediate increase (IRR 1.38, 95% CI 1.01 to 1.90; p = 0.043), whereas inpatient estimates were imprecise. Outpatient sensitivity analyses reduced statistical clarity. This local pharmacotherapy guidance revision coincided mainly with a secondary outpatient prescribing signal. Causality, clinical utility, and patient outcomes cannot be inferred.","PeriodicalId":16645,"journal":{"name":"Journal of Pain & Palliative Care Pharmacotherapy","volume":" ","pages":"1-8"},"PeriodicalIF":1.3,"publicationDate":"2026-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148794487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0